Minimizing the immunogenicity of antibodies for clinical application.


The clinical utility of murine monoclonal antibodies has been greatly limited by the human anti-murine antibody responses they effect in patients. To make them less immunogenic, murine antibodies have been genetically engineered to progressively replace their murine content with that of their human counterparts. This review describes the genetic approaches… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.